STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 – 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of Altuvoct® (efanesoctocog alfa) treatment for haemophilia A, including updates on patients' joint health and surgical outcomes in patients.

"At WFH 2025 CCS, Sobi will present highlights from the XTEND phase 3 program and discuss the new treatment paradigm with FVIII levels in the non-haemophilia range. Sharing these clinical outcomes with the wider haemophilia community will help to ensure the latest treatment approaches are widely known and understood," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.

STOCKHOLM, April 15, 2025 /PRNewswire/ -- Sobi plans to publish its report for the first quarter of 2025 on 29 April 2025 at 08:00 CET.

Investors, analysts, and the media are invited to a conference call on the same day at 15:30 CET, 14:30 GMT, and 09:30 EST. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:Sweden: +46 8 5051 0031United Kingdom: +44 207 107 06 13United States: +1 631 570 56 13For other countries, please find the details here.

STOCKHOLM, April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Thursday, 8 May 2025 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting.

Right to participate and registration

(A) Participation at the meeting venue

STOCKHOLM, April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Thursday, 8 May 2025 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting.

Right to participate and registration

(A) Participation at the meeting venue

STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases. 

Sobi has a strong focus on building a sustainable business and ensuring that everyone eligible within its therapeutic areas has access to approved medicines.

The report includes the audited Annual report and the Sustainability report, which is Sobi's statutory sustainability report in accordance with the Swedish Annual Accounts Act and based on GRI Standards 2021, inspired by the European Sustainability Reporting Standards (ESRS).

STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases. 

Sobi has a strong focus on building a sustainable business and ensuring that everyone eligible within its therapeutic areas has access to approved medicines.

The report includes the audited Annual report and the Sustainability report, which is Sobi's statutory sustainability report in accordance with the Swedish Annual Accounts Act and based on GRI Standards 2021, inspired by the European Sustainability Reporting Standards (ESRS).

STOCKHOLM, March 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS) which is to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress by Prof. Giamarellos-Bourboulis, from the Hellenic Institute for the Study of Sepsis. The study underscores Sobi's commitment to advancing medicine through targeted therapies for severe and complex conditions such as sepsis, a leading cause of mortality globally. 

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. The application was granted Priority Review with a PDUFA date of June 27, 2025.

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.

"C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life," said Lydia Abad-Franch MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. "With no approved treatments currently available, this important milestone reflects our dedication to improving outcomes for those affected by these rare kidney conditions."

STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024.

Fourth Quarter 2024

Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)1, to SEK 7,436 M (6,844)Haematology revenue increased 22 per cent at CER to SEK 4,487 M (3,640), mainly driven by strong sales of Doptelet® of SEK 1,147 M (727), Vonjo® of SEK 416 M (322), Aspaveli®/Empaveli® of SEK 269 M (186) and launch sales of Altuvoct® of SEK 302 M (2)Immunology revenue decreased 12 per cent at CER to SEK 2,564 M (2,905), explained by low Synagis® sales of 68 M (897), partially offset by Beyfortus® royalty of SEK 1,207 M (890) and sales of Kineret® of SEK 777 M (621)Revenue from the strategic portfolio1* grew by 50 per cent at CER to SEK 4,099 M (2,722)The adjusted EBITA margin1,2 was 34 per cent (38), excluding items affecting comparability (IAC)2. EBITA was SEK 2,572 M (2,502), corresponding to a margin of 35 per cent (37). EBIT was SEK 1,662 M (1,610)Earnings per share (EPS) before dilution was SEK 4.07 (3.02). Adjusted EPS before dilution1 was SEK 4.03 (3.21). Cash flow from operating activities was SEK 1,797 M (1,073)David Meek was elected as a new member, and as Chair of the Board of Directors

STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024.

Fourth Quarter 2024

Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)1, to SEK 7,436 M (6,844)Haematology revenue increased 22 per cent at CER to SEK 4,487 M (3,640), mainly driven by strong sales of Doptelet® of SEK 1,147 M (727), Vonjo® of SEK 416 M (322), Aspaveli®/Empaveli® of SEK 269 M (186) and launch sales of Altuvoct® of SEK 302 M (2)Immunology revenue decreased 12 per cent at CER to SEK 2,564 M (2,905), explained by low Synagis® sales of 68 M (897), partially offset by Beyfortus® royalty of SEK 1,207 M (890) and sales of Kineret® of SEK 777 M (621)Revenue from the strategic portfolio1* grew by 50 per cent at CER to SEK 4,099 M (2,722)The adjusted EBITA margin1,2 was 34 per cent (38), excluding items affecting comparability (IAC)2. EBITA was SEK 2,572 M (2,502), corresponding to a margin of 35 per cent (37). EBIT was SEK 1,662 M (1,610)Earnings per share (EPS) before dilution was SEK 4.07 (3.02). Adjusted EPS before dilution1 was SEK 4.03 (3.21). Cash flow from operating activities was SEK 1,797 M (1,073)David Meek was elected as a new member, and as Chair of the Board of Directors

Sobi plans to publish its report for the fourth quarter and full year of 2024 on 5 February 2025 at 08:00 CET.

STOCKHOLM, Jan. 21, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference call on the same day at 14:30 CET, 13:30 GMT, and 08:30 EST. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors for the period until the end of the Annual General Meeting 2025.

Minutes with complete resolutions from the EGM will be available on the company's website www.sobi.com no later than 25 December 2024.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors for the period until the end of the Annual General Meeting 2025.

Minutes with complete resolutions from the EGM will be available on the company's website www.sobi.com no later than 25 December 2024.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registration for the Meeting will begin at 08.30.

The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting.

STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registration for the Meeting will begin at 08.30.

The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting.

The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.

STOCKHOLM, Nov. 4, 2024 /PRNewswire/ -- David Meek currently serves as a member of the Board of Directors of Cullinan Therapeutics, uniQure (Chair) and the University of Southern California School of Pharmacy and Pharmaceutical Sciences. He also has previous experience from board work in listed pharmaceutical companies and US and European trade associations. David Meek has extensive experience from senior positions in the international pharmaceutical industry. Most recently he served as Chief Executive Officer and Board Director of Mirati Therapeutics Inc and prior to that as Chief Executive Officer of FerGene Inc and Ipsen SA. He has also held senior executive positions at Baxalta Inc, Endocyte Inc, Novartis Pharmaceuticals and Johnson & Johnson.

The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.

STOCKHOLM, Nov. 4, 2024 /PRNewswire/ -- David Meek currently serves as a member of the Board of Directors of Cullinan Therapeutics, uniQure (Chair) and the University of Southern California School of Pharmacy and Pharmaceutical Sciences. He also has previous experience from board work in listed pharmaceutical companies and US and European trade associations. David Meek has extensive experience from senior positions in the international pharmaceutical industry. Most recently he served as Chief Executive Officer and Board Director of Mirati Therapeutics Inc and prior to that as Chief Executive Officer of FerGene Inc and Ipsen SA. He has also held senior executive positions at Baxalta Inc, Endocyte Inc, Novartis Pharmaceuticals and Johnson & Johnson.

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocorticoids (GCs) will be presented at the American College of Rheumatology (ACR) Convergence in Washington D.C. The data were pooled from two open-label, single-arm interventional studies, the phase 3 NI-0501-14 study [EMERALD; NCT05001737] and NI-0501-06 [NCT03311854], including 39 patients with MAS.   

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocorticoids (GCs) will be presented at the American College of Rheumatology (ACR) Convergence in Washington D.C. The data were pooled from two open-label, single-arm interventional studies, the phase 3 NI-0501-14 study [EMERALD; NCT05001737] and NI-0501-06 [NCT03311854], including 39 patients with MAS.